经皮雌二醇联合重组人胰岛素样生长因子-1对神经性厌食症年轻女性骨结局的影响
结果显示,安慰剂组腰椎面积骨密度增加优于联合rhIGF-1组(P=0.004),联合rhIGF-1未显示额外获益。
要点
- 经皮雌二醇联合rhIGF-1未在骨密度、几何、微结构或强度上优于单用雌二醇。
- 单用雌二醇组腰椎面积骨密度增加优于联合rhIGF-1组(P=0.004)。
- 联合rhIGF-1组甲状旁腺激素升高(P=0.019),单用雌二醇组骨吸收标志物下降(P=0.042)。
核心结论
- 在神经性厌食症年轻女性中,经皮雌二醇替代治疗基础上加用rhIGF-1 12个月未显示额外骨获益。
主要发现
- 12个月内,单用雌二醇组(AN-IGF-1-)腰椎面积骨密度增加优于联合rhIGF-1组(AN-IGF-1+)(P=0.004)。
- 联合rhIGF-1组在雌二醇治疗依从性可变的情况下,面积骨密度无改善。
- 两组在骨几何、微结构、体积骨密度或强度12个月变化上无差异,控制体重变化后结果不变。
- 两组桡骨皮质面积和体积骨密度及胫骨皮质体积骨密度均随时间增加。
- 单用雌二醇组骨吸收标志物水平下降(P=0.042),联合rhIGF-1组甲状旁腺激素升高(P=0.019)。
关键数值与推荐
- 干预:经皮17β-雌二醇0.1 mg/天,联合rhIGF-1 30 mcg/kg/次皮下注射每日两次或安慰剂;rhIGF-1剂量调整至正常青春期范围上半区。
- 主要结局指标:骨转换标志物及骨密度、几何、微结构和强度估计。
临床怎么用
- 对于神经性厌食症年轻女性的骨损害,经皮雌二醇替代治疗可考虑,但联合rhIGF-1未显示额外获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Anorexia nervosa (AN) is prevalent in adolescent girls and is associated with bone impairment driven by hormonal alterations in nutritional deficiency. OBJECTIVE: To assess the impact of estrogen replacement with and without recombinant human insulin-like growth factor-1 (rhIGF-1) administration on bone outcomes. DESIGN: Double-blind, randomized, placebo-controlled 12-month longitudinal study. PARTICIPANTS: Seventy-five adolescent and young adult women with AN age 14 to 22 years. Thirty-three participants completed the study. INTERVENTION: Transdermal 17-beta estradiol 0.1 mg/day with (i) 30 mcg/kg/dose of rhIGF-1 administered subcutaneously twice daily (AN-IGF-1+) or (ii) placebo (AN-IGF-1-). The dose of rhIGF-1 was adjusted to maintain levels in the upper half of the normal pubertal range. MAIN OUTCOME MEASURES: Bone turnover markers and bone density, geometry, microarchitecture, and strength estimates. RESULTS: Over 12 months, lumbar areal bone mineral density increased in AN-IGF-1- compared to AN-IGF-1+ (P = 0.004). AN-IGF-1+ demonstrated no improvement in areal BMD in the setting of variable compliance to estrogen treatment. Groups did not differ for 12-month changes in bone geometry, microarchitecture, volumetric bone mineral density (vBMD), or strength (and results did not change after controlling for weight changes over 12 months). Both groups had increases in radial cortical area and vBMD, and tibia cortical vBMD over 12 months. Levels of a bone resorption marker decreased in AN-IGF-1- (P = 0.042), while parathyroid hormone increased in AN-IGF-1+ (P = 0.019). AN-IGF-1- experienced irregular menses more frequently than did AN-IGF-1+, but incidence of all other adverse events did not differ between groups. CONCLUSIONS: We found no additive benefit of rhIGF-1 administration for 12 months over transdermal estrogen replacement alone in this cohort of young women with AN.
引用
- Singhal V, Bose A, Slattery M, et al. Effect of Transdermal Estradiol and Insulin-like Growth Factor-1 on Bone Endpoints of Young Women With Anorexia Nervosa. J Clin Endocrinol Metab. 2021. PMID: 33693703. doi:10.1210/clinem/dgab145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。